MPM closes $400 million fund

MPM Capital closed its BioVentures 2014 fund at $400 million. According to an SEC filing from last spring, MPM was looking to raise about $380 million for the fund. The firm's Luke Evnin told BioCentury that MPM already has made six investments from the new fund. They include encapsulated cell therapy company Semma Therapeutics Inc. (Cambridge, Mass.); cancer plays Potenza Therapeutics Inc. (Cambridge, Mass.), Raze Therapeutics Inc. (Cambridge, Mass.), Harpoon Therapeutics and Vesuvius Therapeutics; and fibrosis company FibroRx. ...